

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	225743	gm\$1csf of csf\$1alpha or pluripoietin\$1alpha	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:23
L2	17005	gm\$1csf or csf\$1alpha or pluripoietin\$1alpha	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:23
L3	52330	horse or equine or equus	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:23
L4	5788	2 and 3	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:24
L5	124	2 same 3	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:24
L6	52	2 same 3	USPAT	OR	OFF	2006/09/07 14:29
L7	9	bublot.in.	USPAT	OR	OFF	2006/09/07 14:29
L8	2	bublot.in. and gm\$1csf	USPAT	OR	OFF	2006/09/07 14:29
S1	0	("gm\$1csf.clm.").PN.	USPAT	OR	OFF	2006/05/16 14:24
S2	1575	gm\$1csf.clm.	US-PGPUB; USPAT	OR	OFF	2006/05/16 14:25
S3	128	gm\$1csf.clm. same (administer or administering)	US-PGPUB; USPAT	OR	OFF	2006/09/07 14:23
S4	70	gm\$1csf.clm. same (administer or administering) not (vaccine or vaccination)	US-PGPUB; USPAT	OR	OFF	2006/05/16 14:26
S5	36	gm\$1csf.clm. same (administer or administering) not (vaccine or vaccination)	USPAT	OR	OFF	2006/05/16 14:29
S6	1	"5162111".pn.	USPAT	OR	OFF	2006/05/16 14:29

10/614481 09/07/2006

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009998...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 05.12.03D

Last logoff: 17aug06 08:49:00

Logon file405 07sep06 13:32:26

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

****EMCare (File 45)

***Trademarkscan - South Korea (File 655)

***Regulatory Affairs Journals (File 183)

***Index Chemicus (File 302)

***Inspec (File 202)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

****File 11, PsycInfo

***File 516, D&B--Dun's Market Identifiers

***File 523, D&B European Dun's Market Identifiers

***File 531, American Business Directory

*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)

is now available online.

DATABASES REMOVED

***File 196, FINDEX

***File 468, Public Opinion Online (POLL)

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<<

>>>and events, please visit What's New from Dialog at <<<

>>><http://www.dialog.com/whatsnew/>. You can find news about<<<

>>>a specific database by entering HELP NEWS <file number>.<<<

>>>PROFILE is in a suspended state.

>>>Contact Dialog Customer Services to re-activate it.

* * *

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.7.9 term=ASCII

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)

10/614481 09/07/2006

2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help /L = Logoff /NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

? b 410

```
07sep06 13:32:27 User217743 Session D684.1
$0.00 0.235 DialUnits FileHomeBase
$0.00 Estimated cost FileHomeBase
$0.00 Estimated cost this search
$0.00 Estimated total session cost 0.235 DialUnits
```

File 410:Dialog Comm.-of-Interest News1/Jul (c) 2006 Dialog

Set	Items	Description
?	set hi	;set hi
HIGHLIGHT	set on as	''
HIGHLIGHT	set on as	''
? b 411		
07sep06 13:32:31	User217743 Session D684.2	
\$0.00	0.104 DialUnits File410	
\$0.00	Estimated cost File410	
\$0.02	TELNET	
\$0.02	Estimated cost this search	
\$0.02	Estimated total session cost	0.339 DialUnits

File 411:DIALINDEX(R)

DIALINDEX(R)
(c) 2006 Dialog

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? set files biochem
>>> 76 is unauthorized
>>>1 of the specified files is not available
You have 27 files in your file list.
(To see banners, use SHOW FILES command)
? show files

File	Name
5:	Biosis Previews(R)_1969-2006/Sep W1
6:	NTIS_1964-2006/Aug W4
24:	CSA Life Sciences Abstracts_1966-2006/Jul
34:	SciSearch(R) Cited Ref Sci_1990-2006/Aug W4
40:	Enviroline(R)_1975-2006/Jul
41:	Pollution Abstracts_1966-2006/Jul
45:	EMCare_2006/Sep W1
50:	CAB Abstracts_1972-2006/Aug

10/614481 09/07/2006

65: Inside Conferences_1993-2006/Sep 07
71: ELSEVIER BIOBASE_1994-2006/Sep W1
73: EMBASE_1974-2006/Sep 07
94: JICST-EPlus_1985-2006/May W4
98: General Sci Abs_1984-2005/Jul
103: Energy SciTec_1974-2006/Jul B2
136: BioEngineering Abstracts_1966-2006/Jul
143: Biol. & Agric. Index_1983-2006/Jul
144: Pascal_1973-2006/Aug W2
155: MEDLINE(R)_1950-2006/Sep 06
156: ToxFile_1965-2006/Aug W4
162: Global Health_1983-2006/Aug
172: EMBASE Alert_2006/Sep 07
305: Analytical Abstracts_1980-2006/Aug W3
369: New Scientist_1994-2006/Jul W5
370: Science_1996-1999/Jul W3
393: Beilstein Abstracts_2006/Q3
399: CA SEARCH(R)_1967-2006/UD=14511
434: SciSearch(R) Cited Ref Sci_1974-1989/Dec

? s gm-csf and (horse or equine or equus)

Your SELECT statement is:

s gm-csf and (horse or equine or equus)

Items	File
5	5: Biosis Previews(R)_1969-2006/Sep W1
10	34: SciSearch(R) Cited Ref Sci_1990-2006/Aug W4
2	71: ELSEVIER BIOBASE_1994-2006/Sep W1

3 files have one or more items; file list includes 27 files.

? s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)

Your SELECT statement is:

s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)

Items	File
5	5: Biosis Previews(R)_1969-2006/Sep W1
10	34: SciSearch(R) Cited Ref Sci_1990-2006/Aug W4
2	71: ELSEVIER BIOBASE_1994-2006/Sep W1

3 files have one or more items; file list includes 27 files.

? b 5

07sep06 13:34:05 User217743 Session D684.3
\$3.99 1.504 DialUnits File411
\$3.99 Estimated cost File411
\$0.53 TELNET
\$4.52 Estimated cost this search
\$4.54 Estimated total session cost 1.843 DialUnits

File 5:Biosis Previews(R) 1969-2006/Sep W1
(c) 2006 The Thomson Corporation

Set Items Description

? s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)
3521 GM-CSF
58190 CSF

10/614481 09/07/2006

703126 ALPHA
75 CSF(W) ALPHA
19 PLURIPOIETIN
703126 ALPHA
4 PLURIPOIETIN(W) ALPHA
39777 HORSE
17166 EQUINE
2118 EQUUS
S1 5 (GM-CSF OR CSF()ALPHA OR PLURIPOIETIN()ALPHA) AND (HORSE
OR EQUINE OR EQUUS)

? t s1/3,ab/all

1/3,AB/1
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015575811 BIOSIS NO.: 200510270311
Blood from mesenchymal stem cell.
AUTHOR: Lange Claudia (Reprint); Gehling Ursula; Moosmann Sabine; Huss Ralf
; Zander Axel R
AUTHOR ADDRESS: Univ Hamburg Hosp, BMT Ctr, D-2000 Hamburg, Germany**
Germany
JOURNAL: Blood 104 (11, Part 1): p644A NOV 16 2004 2004
CONFERENCE/MEETING: 46th Annual Meeting of the
American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Mesenchymal stem cells (MSC) have been described to support the maintainance and expansion of clonogenic hematopoietic cells in vitro and as progenitors for nonhematopoietic tissues. They clearly can be distinguished from hematopoietic cells by the surface markers CD45 and CD34. We investigated the potential of human MSC to form blood and endothelial cells. Human MSC in expansion cultures expressed RNA for CD 117 and EpoR but not for other hematopoietic antigens. Many transcription factors essential for blood cell differentiation, e.g. c-mpl, Notch- 1, Gata-2 and -3, Runx-1 and SCL, were detected in these cells. We used different differentiation strategies: A) Hematopoietic differentiation:
1. Prestimulation in IMDM + fetal calf serum (FCS) + horse serum (HS), mixed with methylcellulose (MC, containing cytokines SCF, IL-3, IL-6, G-CSF, GM-CSF and Epo) and differentiation in MC; 2. Prestimulation in serum free medium supplemented with SCF, TPO, GM-CSF and flt.- 3 ligand and differentiation in serum free MC; B) Endothelial differentiation: Prestimulation in serum free medium supplemented with SCF, TPO, and flt-3L and differentiation in medium + VEGF + bFGF + IGF. Using FACS-analysis, we detected up to 1.8 % CD34-positive cells within 2 weeks. Immunohistochemically we observed cells positive for CD45, CD34, CD133, CD14, CD16 and CD41. Although hMSC do not form colonies after seeding in MC, after prestimulation we observed colonies with the typical appearance of BFU-E which were GlycophorinA positive. Under endothelial conditions we detected cells positive for CD34 and KDR or CD31 and vWF. However, cell numbers of positive cells were low and therefore RT-PCR results were not very reliable. To confirm the differentiation capacity of MSC we generated CD45.2 mouse MSC (P9 what took about 6 month) and transplanted into lethally irradiated CD45.1 recipient mice. Four weeks after transplantation mice showed normal white blood cell counts but still decreased platelet counts. Analysis of donor chimerism 29 weeks after transplantation revealed up to 36 % (14.3 +/- 7.9%) donor cells in peripheral blood, mainly in the CD11b positive myeloid population but not

10/614481 09/07/2006

in lymphoid cells. In thymus and bone marrow, marginal donor chimerism (3 +/- 0.8%) was detected, but the number in c-kit+ cells reached up to 28.2% (7.9 +/- 6.8%). In B-cells and erythroid progenitors chimerism was low but stable, but not in CD3+ cells. Taken together, we have shown that under the right conditions MSC are able to form blood and endothelial cells and reconstitute animals. We suggest that MSC could be an yet unrecognised precursor for both cell types and may contain the long searched hemangioblast in adult organisms.

1/3,AB/2
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014399081 BIOSIS NO.: 200300357800
Unacceptable Toxicity Associated with Recombinant Human Interleukin-11
(rhIL-11) Therapy in Children with Severe Aplastic Anemia.
AUTHOR: Hord Jeffrey (Reprint); Blatt Julie; Rogers Zora; Dinndorf Patricia
; Alvarado Carlos; Pediatric Aplastic Anemia Cooperative Trial Group
AUTHOR ADDRESS: Pediatric Hematology/Oncology, Children's Hospital Medical
Center, Akron, OH, USA**USA
JOURNAL: Blood 100 (11): pAbstract No. 3529 November 16, 2002 2002
MEDIUM: print
CONFERENCE/MEETING: 44th Annual Meeting of the American Society of
Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: A randomized multi-institutional clinical trial comparing two combinations of immunosuppressive agents and cytokines in newly diagnosed children with acquired severe aplastic anemia (PAACT3) opened for enrollment in April 2000. Regimen A consisted of horse anti-human thymocyte globulin (ATG) 20 mg/kg/day IV days 1-8, cyclosporine A 5 mg/kg PO twice daily long-term, and GM-CSF (Leukine, Immunex) 250 mcg/m²/day SC long-term. Regimen B was the same as Regimen A but also contained rhIL-11 (Neumega, Wyeth-Ayerst) 75mcg/kg/day SC long-term for those \leq 13 years of age and 50 mcg/kg/d SC long-term for those $>$ 13 years of age. Six of the first 11 children enrolled were randomized to regimen B. Four of the 6 experienced grade 3 toxicity attributed to rhIL-11 requiring the discontinuation of the medication. The observed toxic effects resolved promptly after stopping rhIL-11. The other 2 patients enrolled on regimen B did not experience grade 3/4 toxicity and were younger (18 months and 3 years). Similar toxicities were also not observed in the 5 children enrolled on Regimen A lacking the rhIL-11. The unacceptable level of rhIL-11 toxicity may be related to dose, duration of therapy, patient size, or concomitant administration with ATG and GM-CSF. Due to the high frequency of severe adverse reactions associated with Regimen B, the rhIL-11 dose and schedule was modified based upon the experience of others studying rhIL-11 in the treatment of hepatitis C and myelodysplasia. The dose of rhIL-11 was modified to 50mcg/kg SC three times a week for all ages and PAACT3 study is open for accrual. Patients are being closely monitored for additional toxicities.

1/3,AB/3
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013935550 BIOSIS NO.: 200200529061
Identification of monoclonal antibodies that cross-react with cytokines

10/614481 09/07/2006

from different animal species

AUTHOR: Pedersen L G; Castelruiz Y; Jacobsen S; Aasted B (Reprint)

AUTHOR ADDRESS: Department of Veterinary Microbiology, Immunological
Laboratory, The Royal Veterinary and Agricultural University, Stigbojlen
7, Frederiksberg C, DK-1870, Copenhagen, Denmark**Denmark

JOURNAL: Veterinary Immunology and Immunopathology 88 (3-4): p111-122 25
September, 2002 2002

MEDIUM: print

ISSN: 0165-2427

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Eleven monoclonal antibodies specific for ovine, bovine and human cytokines were investigated by flow cytometry for cross-reactivities with cytokines produced by peripheral blood mononuclear cells (PBMCs) from sheep, cattle, goat, swine, horse, dog, mink, rabbit and human. Four antibodies specific for IL-4, IL-8, IFN-gamma and TNF-alpha cross-reacted with cytokines from a majority of the species investigated. These antibodies can be applied to flow cytometric studies of cytokine production by PBMCs from several veterinary species. Another five antibodies specific for IL-2, IL-6, GM-CSF and IFN-gamma (two antibodies) cross-reacted weakly and with a variable number of animal species. These antibodies could in certain situations be useful in flow cytometry. In a number of cases the immunological cross-reactivities were confirmed by Western blot analyses. Overall, the results of this study will remedy some of the lack of species-specific anti-cytokine antibodies in veterinary research.

1/3,AB/4

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013704795 BIOSIS NO.: 200200298306

Equine immunology: Offspring of the serum horse

AUTHOR: Steinbach Falko (Reprint); Deeg Cornelia; Mauel Susanne; Wagner
Bettina

AUTHOR ADDRESS: Institute of Virology, FU Berlin, Koenigin-Luise-Str. 49,
14195, Berlin, Germany**Germany

JOURNAL: Trends in Immunology 23 (5): p223-225 May, 2002 2002

MEDIUM: print

ISSN: 1471-4906

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The history of veterinary medicine is closely associated with horses. Owing to their military potential, they were the first patients of the veterinary schools founded in the 18th century. Today, horses are no longer of such military interest and live as companion animals with humans. However, recent progress in equine immunology has shed new light on the equine immune system and this knowledge can be applied to develop disease models in horses that might be important for other species, including humans.

1/3,AB/5

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0011477976 BIOSIS NO.: 199800272223

Comparable TNF-alpha, IFN-gamma and GM-CSF production by purified normal

10/614481 09/07/2006

marrow CD3 cells in response to horse anti-lymphocyte and rabbit antithymocyte globulin
AUTHOR: Piaggio G (Reprint); Podesta M; Pitto A; Pittaluga G B; Isaza A; Benvenuto F; Bruno B; Bacigalupo A
AUTHOR ADDRESS: Sci. Bio. Dep. Haematol. 2, San Martino Hosp., Largo Rosanna Benzi 10, 16132 Genova, Italy**Italy
JOURNAL: European Journal of Haematology 60 (4): p240-244 April, 1998 1998
MEDIUM: print
ISSN: 0902-4441
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: In vitro priming of T cell with horse antilymphocyte globulin (HALG) results in cytokine release, and this has been associated with its clinical efficacy in patients with severe aplastic anaemia (SAA). Rabbit antithymocyte globulin (RATG) has been studied less extensively. In this study we compare the in vitro priming effect of HALG and RATG on purified normal marrow T cells: end-points of the study were 1) levels of TNF-alpha (TNF-alpha), IFN-gamma (IFN-gamma) GM-CSF in T cell supernatants, and 2) effect of T cell supernatants on colony formation with or without exogenous GM-CSF. TNF-alpha, IFN-gamma and GM-CSF levels were comparable for HALG, RATG and phytohaemagglutinin (PHA). T cell supernatants showed comparable enhancement of colony formation in the presence of recombinant human GM-CSF (rhGM-CSF) and supported colony forming unit granulomacrophage (CFU-GM) growth in the absence of growth factor. This study shows that horse and rabbit derived ALG/ATG and PHA have a comparable in vitro priming effect on T cells: both agents should probably be tested for their clinical efficacy in SAA patients.

? b 411

```
07sep06 13:34:48 User217743 Session D684.4
$2.66 0.443 DialUnits File5
$11.00 5 Type(s) in Format 4 (UDF)
$11.00 5 Types
$13.66 Estimated cost File5
$0.26 TELNET
$13.92 Estimated cost this search
$18.46 Estimated total session cost 2.286 DialUnits
```

File 411:DIALINDEX(R)

DIALINDEX(R)
(c) 2006 Dialog

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? show files

File Name

? set files allscience
You have 296 files in your file list.
(To see banners, use SHOW FILES command)
? s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)

Your SELECT statement is:
s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)

Items File

5 5: Biosis Previews(R)_1969-2006/Sep W1

10/614481 09/07/2006

10 34: SciSearch(R) Cited Ref Sci_1990-2006/Aug W4
2 71: ELSEVIER BIOBASE_1994-2006/Sep W1
Examined 50 files
Examined 100 files
Examined 150 files
8 348: EUROPEAN PATENTS_1978-2006/ 200636
17 349: PCT FULLTEXT_1979-2006/UB=20060831UT=20060824
7 440: Current Contents Search(R)_1990-2006/Sep 07
Examined 200 files
Examined 250 files
39 654: US Pat.Full._1976-2006/Aug 31

7 files have one or more items; file list includes 296 files.

? rf

Your last SELECT statement was:

S (GM-CSF OR CSF()ALPHA OR PLURIPOIETIN()ALPHA) AND (HORSE OR EQUINE OR EQUUS)

Ref	Items	File
N1	39	654: US Pat.Full._1976-2006/Aug 31
N2	17	349: PCT FULLTEXT_1979-2006/UB=20060831UT=20060824
N3	10	34: SciSearch(R) Cited Ref Sci_1990-2006/Aug W4
N4	8	348: EUROPEAN PATENTS_1978-2006/ 200636
N5	7	440: Current Contents Search(R)_1990-2006/Sep 07
N6	5	5: Biosis Previews(R)_1969-2006/Sep W1
N7	2	71: ELSEVIER BIOBASE_1994-2006/Sep W1
N8	0	2: INSPEC_1898-2006/Aug W4
N9	0	6: NTIS_1964-2006/Aug W4
N10	0	8: Ei Compendex(R)_1970-2006/Aug W4

7 files have one or more items; file list includes 296 files.

- Enter P or PAGE for more -

? b n2, n4, n5, n7

07sep06 13:37:01 User217743 Session D684.5
\$12.33 4.652 DialUnits File411
\$12.33 Estimated cost File411
\$0.80 TELNET
\$13.13 Estimated cost this search
\$31.59 Estimated total session cost 6.938 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 349:PCT FULLTEXT 1979-2006/UB=20060831UT=20060824
(c) 2006 WIPO/Thomson

*File 349: For important information about IPCR/8 and forthcoming changes to the IC= index, see HELP NEWSIPCR.

File 348:EUROPEAN PATENTS 1978-2006/ 200636
(c) 2006 European Patent Office

*File 348: For important information about IPCR/8 and forthcoming changes to the IC= index, see HELP NEWSIPCR.

File 440:Current Contents Search(R) 1990-2006/Sep 07
(c) 2006 The Thomson Corp

File 71:ELSEVIER BIOBASE 1994-2006/Sep W1
(c) 2006 Elsevier B.V.

Set Items Description

? s (gm-csf or csf()alpha or pluripoietin()alpha) and (horse or equine or equus)
4416 GM-CSF
87927 CSF
1173971 ALPHA
124 CSF(W)ALPHA
17 PLURIPOIETIN

10/614481 09/07/2006

```
1173971 ALPHA
      2 PLURIPOIETIN(W) ALPHA
      51827 HORSE
      32392 EQUINE
      2552 EQUUS
S1      34 (GM-CSF OR CSF()ALPHA OR PLURIPOIETIN()ALPHA) AND (HORSE
      OR EQUINE OR EQUUS)
? s s1 and py>1998
      34 S1
      12957652 PY>1998
S2      25 S1 AND PY>1998
? s s1 and py>1999
      34 S1
      11460264 PY>1999
S3      25 S1 AND PY>1999
? s s1 not s3
      34 S1
      25 S3
S4      9 S1 NOT S3
? rd

>>>Duplicate detection is not supported for File 349.

>>>Duplicate detection is not supported for File 348.

>>>Records from unsupported files will be retained in the RD set.
>>>Record 440:6747391 incomplete bibliographic data - record retained in RD set
      S5      9 RD (unique items)
? t s5/3,ab/all

5/3,AB/1 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.
```

00448985

COMPOSITIONS AND USE OF M-CSF-alpha
COMPOSITIONS ET UTILISATIONS DE M-CSF-alpha

Patent Applicant/Assignee:

CHIRON CORPORATION,
DWARKI Varavani,
MANNING William C,
KOTHS Kirston E,

Inventor(s):

DWARKI Varavani,
MANNING William C,
KOTHS Kirston E,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9839449 A1 19980911
Application: WO 98US4802 19980304 (PCT/WO US9804802)
Priority Application: US 9738583 19970304

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN GH GM KE LS MW SD SZ UG
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 25218

English Abstract

The invention is a method and composition for reducing a population of

diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSFalpha mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combination of therapeutic agents including gene delivery vehicles expressing M-CSFalpha or an M-CSFalpha mutant in combination, for example, either with a soluble M-CSF, an M-CSFalpha convertase inhibitor, or a gene delivery vehicle expressing prodrug activator such as thymidine kinase followed by administration of the prodrug.

French Abstract

La presente invention concerne un procede et une composition permettant de reduire une population de cellules malades par administration d'un excipient de delivrance d'un gene, excipient susceptible d'exprimer un mutant de M-CSFalpha presentant une aptitude diminuee a etre traite par la voie proteolytique et a etre libere a partir de la membrane d'une cellule. Cette invention concerne egalement une combinaison d'agents therapeutiques contenant des excipients de delivrance d'un gene exprimant M-CSFalpha ou un mutant de M-CSFalpha en combinaison, par exemple, que ce soit avec un M-CSF soluble, un inhibiteur de M-CSFalpha convertase, ou un excipient de delivrance d'un gene exprimant un activateur de promedicament, tel que la thymidine kinase, a la suite de l'administration du promedicament.

5/3,AB/2 (Item 2 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

00383692

GENES AND GENE PRODUCTS RELATED TO WERNER'S SYNDROME
GENES ET PRODUITS GENIQUES ASSOCIES AU SYNDROME DE WERNER

Patent Applicant/Assignee:

DARWIN MOLECULAR CORPORATION,
OSHIMA Junko,

Inventor(s) :

OSHIMA Junko,
FU Ying-Hui,
YU Chang-En,
MULLIGAN John,
SCHELLENBERG Gerald D,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9724435 A1 19970710
Application: WO 96US20785 19961230 (PCT/WO US9620785)
Priority Application: US 959409 19951229; US 95580539 19951229; US 9610835 19960130; US 96594242 19960130; US 96632175 19960412

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG
KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 21877

English Abstract

The present invention discloses nucleic acid molecules encoding WRN gene products, expression vectors and host cells suitable for expressing such products.

French Abstract

10/614481 09/07/2006

La presente invention concerne des molecules d'acide nucleique codant des produits geniques WRN, des vecteurs d'expression et des cellules hotes permettant d'exprimer ces produits.

5/3,AB/3 (Item 3 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

00362867

CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO ALZHEIMER'S DISEASE
GENE DU CHROMOSOME 1 ET PRODUITS GENETIQUES LIES A LA MALADIE D'ALZHEIMER
Patent Applicant/Assignee:

DARWIN MOLECULAR CORPORATION,
VA MEDICAL CENTER,
THE GENERAL HOSPITAL CORPORATION,
LEVY-LAHAD Ephrat,

Inventor(s):

LEVY-LAHAD Ephrat,
TANZI Rudolph E,
SCHELLENBERG Gerard D,
WASCO Wilma,
BIRD Thomas D,
MULLIGAN John,
GALAS David J,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9703192 A2 19970130
Application: WO 96US11386 19960705 (PCT/WO US9611386)
Priority Application: US 95956 19950707; US 951675 19950728; US 952174
19950811; US 952328 19950814

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

CA JP MX AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 23884

English Abstract

The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.

French Abstract

La presente invention concerne des molecules d'acide nucleique codant pour les produits d'expression genetique AD4, les vecteurs d'expression et les cellules hotes pour exprimer de tels produits genetiques. On decrit egalement des procedes pour traiter, prevenir et diagnostiquer la maladie d'Alzheimer.

5/3,AB/4 (Item 4 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

00324420

A METHOD OF SELECTING PLURIPOTENT HEMATOPOIETIC PROGENITOR CELLS
PROCEDE DE SELECTION DE CELLULES PRECURSEURS HEMATOPOIETIQUES A
POTENTIALITES NON FIXEES

Patent Applicant/Assignee:

NEW ENGLAND DEACONESS HOSPITAL CORPORATION,
Inventor(s):
SCADDEN David T,

10/614481 09/07/2006

Patent and Priority Information (Country, Number, Date):

Patent: WO 9606928 A1 19960307
Application: WO 95US11056 19950831 (PCT/WO US9511056)
Priority Application: US 94299903 19940901

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 8992

English Abstract

Methods of selecting a population of human cells containing quiescent pluripotent hematopoietic progenitor cells substantially free of mature, human myeloid and lymphoid cells, the quiescent pluripotent progenitor cells obtained by these methods, and methods of using the pluripotent progenitor cells are described.

French Abstract

L'invention concerne des procedes de selection d'une population de cellules humaines contenant des cellules precurseurs hematopoietiques et quiescentes, dont les potentialites ne sont pas fixees et qui sont sensiblement exemptes de cellules humaines myeloïdes et lymphoides matures, les cellules precurseurs quiescentes obtenues au moyen desdits procedes, ainsi que des procedes d'utilisation desdites cellules.

5/3,AB/5 (Item 5 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2006 WIPO/Thomson. All rts. reserv.

00311854

THYMIDINE KINASE MUTANTS

MUTANTS DE LA THYMIDINE KINASE

Patent Applicant/Assignee:

UNIVERSITY OF WASHINGTON,

Inventor(s):

LOEB Lawrence A,
BLACK Margaret E,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9530007 A1 19951109
Application: WO 95US5561 19950502 (PCT/WO US9505561)
Priority Application: US 94237592 19940502

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LT LV
MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG UZ VN KE MW SD
SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 32024

English Abstract

The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution upstream from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within another aspect, one of the mutations is an amino acid substitution within a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Also provided are vectors suitable for expressing such

DNA molecules, as well as methods for utilizing such vectors.

French Abstract

L'invention porte sur des molecules d'acide nucleique isolees codant pour l'enzyme thymidine kinase du Herpesviridae presentant une ou plusieurs mutations, dont une au moins code pour une substitution d'acide amine en amont du site de fixation du nucleoside DRH, laquelle accroit l'activite biologique de la thymidine kinase par rapport a celle qu'elle presente sans mutation. Dans une variante, l'une des mutations consiste en une substitution d'acide amine a l'interieur du site de fixation du nucleoside DRH, laquelle accroit l'activite biologique de la thymidine kinase par rapport a celle qu'elle presente sans mutation. L'invention porte egalement sur des vecteurs susceptibles d'exprimer lesdites molecules d'ADN et sur leurs modes d'utilisation.

5/3,AB/6 (Item 6 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

00170568

PRIMITIVE CELL COLONY STIMULATING FACTORS AND LYMPHOHEMATOPOIETIC PROGENITOR CELLS
FACTEURS DE STIMULATION DE COLONIES DE CELLULES PRIMITIVES ET CELLULES SOUCHES LYMPHOHEMATOPOIETIQUES

Patent Applicant/Assignee:

UNIVERSITY OF SASKATCHEWAN,
HEISE-QUALTIERE Janette,

Inventor(s):

HEISE-QUALTIERE Janette,
LAWMAN Michael J P,
OHMANN Helle Bielefeldt,
ATTAH-POKU Samuel K,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9004018 A1 19900419
Application: WO 89US4452 19891006 (PCT/WO US8904452)
Priority Application: US 8888 19881007

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AT AU BE CH DE DK FI FR GB IT JP KR LU NL NO SE

Publication Language: English

Fulltext Word Count: 14839

English Abstract

The invention derives from the discovery of cells, NA cells, which have properties indicating that they may be pluripotent lymphohematopoietic progenitor cells. These cells, and the stromal cells derived from bone marrow cultures, produce factors which stimulate the growth of primitive cell colonies, as reflected in their stimulation of the growth of colonies of NA cells. These primitive cell colony stimulating factors (PC-CSFs) may be useful in the treatment of disorders which can be alleviated by the proliferation of desired cells. In addition, the NA cells and/or PC-CSFs) may provide an alternative and/or supplementary method to bone marrow transplantation to alleviate hematopoietic disorders.

French Abstract

L'invention se fonde sur la decouverte de cellules, les cellules non adherentes, qui ont des proprietes indiquant qu'elles pourraient etre des cellules souches lymphohematopoietiques pluripotentes. Ces cellules, ainsi que les cellules du stoma derivees de cultures de moelle osseuse, produisent des facteurs qui stimulent la croissance de colonies de

10/614481 09/07/2006

cellules primitives, comme le reflete la stimulation qu'elles exercent sur la croissance de colonies de cellules non adherentes. Ces facteurs de stimulation de colonies de cellules primitives (PC-CSFs) peuvent etre utiles dans le traitement de troubles que peut attenuer la proliferation de cellules donnees. De plus, les cellules non adherentes et/ou les facteurs de stimulation de colonies de cellules primitives peuvent servir de methode de rechange et/ou de methode complementaire a la transplantation de moelle osseuse visant a attenuer les troubles hematopoietiques.

5/3,AB/7 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

08431155 References: 28
TITLE: Factors controlling haemopoiesis in ovine long term bone marrow cultures
AUTHOR(S): Marsicano G; Shehu D; Galli C (REPRINT)
CORPORATE SOURCE: CIZ SRL, LAB TECNOL RIPROD, VIA PORCELLASCO 7-F/I-26100
CREMONA//ITALY/ (REPRINT); CIZ SRL, LAB TECNOL RIPROD/I-26100
CREMONA//ITALY/
PUBLICATION TYPE: JOURNAL
PUBLICATION: VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, V55, N4 (MAR)
, P291-301
GENUINE ARTICLE#: WY051
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISSN: 0165-2427
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: We describe an adaptation of the Dexter technique for obtaining ovine long term bone marrow cultures able to sustain haemopoiesis in vitro for long periods. Two inocula of bone marrow cells collected at three-five weeks interval, in IMDM supplemented with fetal calf serum (10%), horse serum (10%) and hydrocortisone (5×10^{-7} M), gave rise to the growth of an adherent cell layer which supported, in most cases, active haemopoiesis for up to 15 weeks. The cell layer was composed of macrophages, fibroblasts and adipocytes. Haemopoietic cells formed large foci of 'cobblestone' areas. Haemopoietic progenitors were also released into the supernatant medium and were detectable by clonogenic assay. Granulocytes and monocyte-macrophages differentiated in the cultures in constant proportion until week five, when the monocytic lineage superseded the myelocytic one. These cultures, between weeks five and twelve, produced colony forming cells in a constant pattern, indicating the presence and self renewing of early haemopoietic progenitor cells. (C) Elsevier Science B.V.

5/3,AB/8 (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

06747391
PUBLICATION: BIOLOGY OF REPRODUCTION, 1995
ISSN: 0006-3363

5/3,AB/9 (Item 3 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

05391600 References: 28
TITLE: CHARACTERIZATION OF A HUMAN CELL LINE (NK-92) WITH PHENOTYPICAL AND

10/614481 09/07/2006

FUNCTIONAL CHARACTERISTICS OF ACTIVATED NATURAL KILLER CELLS

AUTHOR(S): GONG JH; MAKI G; KLINGEMANN HG (Reprint)

CORPORATE SOURCE: UNIV BRITISH COLUMBIA, BRITISH COLUMBIA CANC

AGCY/VANCOUVER/BC/CANADA/ (Reprint); UNIV BRITISH COLUMBIA, BRITISH COLUMBIA CANC AGCY/VANCOUVER/BC/CANADA/; UNIV BRITISH COLUMBIA, TERRY FOX LAB/VANCOUVER/BC/CANADA/; UNIV BRITISH COLUMBIA, DIV HEMATOL/VANCOUVER/BC/CANADA/

PUBLICATION: LEUKEMIA, 1994, V8, N4 (APR), P652-658

GENUINE ARTICLE#: NJ517

ISSN: 0887-6924

LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE

ABSTRACT: The cell line described here was established for a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma whose marrow was diffusely infiltrated with large granular lymphocytes (LGL). Immunophenotyping of marrow blasts and peripheral lymphocytes was positive for CD56, CD2 and CD7, and negative for CD3. Cytotoxicity of peripheral blood mononuclear cells at an effector:target (E:T) cell ratio of 50:1 was 79% against K562 cells and 48% against Daudi cells. To establish the line, cells from the peripheral blood were placed into enriched alpha medium containing 12.5% fetal calf serum, 12.5% horse serum, 10(-4) M beta-mercaptoethanol and 10(-6) M hydrocortisone. Growth of the line (termed NK-92) is dependent on the presence of recombinant IL-2 and a dose as low as 10 U/ml is sufficient to maintain proliferation. Conversely, cells die within 72 h when deprived of IL-2; IL-7 and IL-12 do not maintain long-term growth, although IL-7 induces short-term proliferation measured by H-3-thymidine incorporation. None of the other cytokines tested (IL-1 alpha, IL-6, INF-alpha, IFN-alpha, IFN-gamma) supported growth of NK-92 cells which have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54, CD56(bright); surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34, HLA-DR. DNA analysis showed germline configuration for T-cell receptor beta and gamma genes. CD25 (p55 IL-2 receptor) is expressed on about 50% of all cells when tested at 100 U/ml of IL-2 and its expression correlates inversely with the IL-2 concentration. The p75 IL-2 receptor is expressed on about half of the cells at low density irrespective of the IL-2 concentration. NK-92 cells kill both K562 and Daudi cells very effectively in a 4 h(51)-chromium release assay (84 and 86% respectively, at an E:T cell ratio of 5:1). The cell line described here thus displays characteristics of activated NK-cells and could be a valuable tool to study their biology.

? d his

>>>'HIS' not recognized as set or accession number

? ds

Set	Items	Description
S1	34	(GM-CSF OR CSF()ALPHA OR PLURIPOIETIN()ALPHA) AND (HORSE OR EQUINE OR EQUUS)
S2	25	S1 AND PY>1998
S3	25	S1 AND PY>1999
S4	9	S1 NOT S3
S5	9	RD (unique items)

? logoff

07sep06 13:39:02	User217743	Session D684.6
\$1.80	0.378	DialUnits File349
\$32.70	6	Type(s) in Format 5 (UDF)
\$32.70	6	Types
\$34.50	Estimated cost	File349
\$2.92	0.540	DialUnits File348
\$2.92	Estimated cost	File348
\$27.05	1.110	DialUnits File440
\$6.64	1	Type(s) in Format 3 (UDF)
\$13.28	2	Type(s) in Format 4 (UDF)

10/614481 09/07/2006

\$19.92 3 Types
\$46.97 Estimated cost File440
\$2.32 0.264 DialUnits File71
\$2.32 Estimated cost File71
OneSearch, 4 files, 2.292 DialUnits FileOS
\$0.80 TELNET
\$87.51 Estimated cost this search
\$119.10 Estimated total session cost 9.230 DialUnits
Logoff: level 05.12.03 D 13:39:02